Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

In Brief: Monistat 3

This article was originally published in The Tan Sheet

Executive Summary

Monistat 3: TV ad for J&J's miconazole vaginal yeast infection treatment alerts women that the "new one-dose yeast infection ointment" does not "cure a yeast infection in one day." The first to target Bristol-Myers Squibb's Vagigstat One tioconazole switch product, the ad notes that the "other product" does not "cure faster than Monistat 3," and that "three out of four gynecologists prefer Monistat 3 over the one-dose ointment." The ad, with spokeperson Kim Alexis, ends with the tagline, "Monistat. The number one doctor recommended cure." J&J also is running print ads with the tagline, "Nothing, absolutely nothing, cures a yeast infection faster than Monistat 3"...

You may also be interested in...



Supplement GMP Warning Letters Make Modest Debut In 2010

Finalization of a settlement between the Federal Trade Commission and Rexall Sundown regarding unsupported cellulite treatment claims for the firm's Cellasene dietary supplement hinges upon approval of two related class action settlements pending in California and Florida, according to FTC

In Brief

Combe sells most of its OTC brands

People In Brief

Perrigo promotes in pricing, planning

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

PS087175

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel